PHIO Phio Pharmaceuticals Corp.

RXi Pharmaceuticals Corp is principally engaged in developing therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs.

$2.20
As of 06/18/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  11/19/2018
Outstanding shares:  13,534,389
Average volume:  506,330
Market cap:   $30,858,407
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    71880W303
ISIN:        US71880W3034
Sedol:      BKV2996
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.95
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy